Last update Feb. 5, 2022
Inorganic compound that is used in systemic administration as an antidote for cyanide poisoning and in extravasations of certain antineoplastic drugs and, used topically, as an antifungal. It has been used in infants from one month of age.
At the date of the last update, there was no published data available on its excretion in human milk.
Its pharmacokinetic data do not allow to predict whether it’s possible for it to be excreted in breastmilk.
Its low oral bioavailability (Farese 2011) makes it difficult for the infant to pass into plasma from ingested mothers’ milk, except in premature infants and during the immediate neonatal period in which there may be greater intestinal permeability.
Given its short half-life (Shea 1984), it is possible to breastfeed again 6 hours after the last administration of the drug if the mother's clinical status allows it.
WHO List of Essential Medicines: topical dermatological application of sodium thiosulfate is compatible with breastfeeding.(WHO 2002)
We do not have alternatives for Sodium Thiosulphate.
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
e-lactancia is a resource recommended by Asociación Pro Lactancia Materna (APROLAM) of Mexico
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM